No Data
No Data
Pharmaceutical stocks fluctuated and adjusted. Qianyuan Pharmaceutical fell more than 10%, Kyodo Pharmaceutical fell more than 7%, and Luoxin Pharmaceutical, Hehua Co., Ltd., Erkang Pharmaceutical, and Cube Pharmaceutical had the highest declines.
Pharmaceutical stocks fluctuated and adjusted. Qianyuan Pharmaceutical fell more than 10%, Kyodo Pharmaceutical fell more than 7%, and Luoxin Pharmaceutical, Hehua Co., Ltd., Erkang Pharmaceutical, and Cube Pharmaceutical had the highest declines.
Erkang Pharmaceutical (300267.SZ): Net profit of 2.9015 million yuan in the first quarter decreased by 88.87% year on year
Gelonghui, April 26 | Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 276 million yuan, down 49.57% year on year; net profit attributable to shareholders of listed companies was 2.9015 million yuan, down 88.87% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 3.3425 million; basic earnings per share.
Erkang Pharmaceutical (300267.SZ) announced its 2023 annual results, with a net loss of 195 million yuan from profit to loss
According to Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its 2023 annual results report. During the reporting period, the company achieved operating income of 1,783 million yuan, a year-on-year decrease of 4.67%; net loss attributable to shareholders of listed companies of 195 million yuan, and net profit of 459.44,900 yuan in the same period last year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 232 million yuan; basic loss per share.
Express News | Erkang Pharmaceutical: Expected net profit loss of 148 million yuan to 198 million yuan in 2023
Erkang Pharmaceutical (300267.SZ): The sale of the third batch of shares of the 2020 Employee Stock Ownership Plan has been completed
Gelonghui on December 26丨Erkang Pharmaceutical (300267.SZ) announced that as of the disclosure date of this announcement, the third batch of shares of the 2020 Employee Stock Ownership Plan has been sold. After the third batch of shares of the 2020 Employee Stock Ownership Plan was sold, the company's employee stock ownership plan account no longer held the company's shares, and this time the employee stock ownership plan was terminated.
Erkang Pharmaceutical (300267.SZ): The company and wholly-owned subsidiaries have passed the re-certification of high-tech enterprises
Gelonghui December 26丨Erkang Pharmaceutical (300267.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Hunan Provincial Department of Science and Technology, the Hunan Provincial Department of Finance, and the Hunan Provincial Taxation Bureau of the State Administration of Taxation, and the Hunan Provincial Taxation Bureau. The company has passed the new certification as a high-tech enterprise. Hunan Xiangyikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Hunan Provincial Department of Science and Technology, the Hunan Provincial Department of Finance, and the Hunan Provincial Taxation Bureau of the State Administration of Taxation, and the Hunan Provincial Taxation Bureau. Xiang Yikang passed the new certification as a high-tech enterprise.
No Data